Xponance Inc. Purchases 86 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Xponance Inc. increased its position in ICU Medical, Inc. (NASDAQ:ICUI) by 5.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,714 shares of the medical instruments supplier’s stock after purchasing an additional 86 shares during the quarter. Xponance Inc.’s holdings in ICU Medical were worth $238,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC boosted its position in ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 153 shares in the last quarter. SG Americas Securities LLC bought a new stake in ICU Medical during the 1st quarter valued at $859,000. Vanguard Group Inc. boosted its position in ICU Medical by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier’s stock valued at $416,176,000 after acquiring an additional 17,805 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in ICU Medical during the 1st quarter valued at $235,000. Finally, Norges Bank acquired a new stake in shares of ICU Medical in the 4th quarter worth $40,151,000. Institutional investors own 96.10% of the company’s stock.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, Director David C. Greenberg sold 1,942 shares of the company’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $143.66, for a total value of $278,987.72. Following the completion of the transaction, the director owned 6,760 shares in the company, valued at $971,141.60. This represents a 22.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Ben Sousa sold 2,000 shares of the company’s stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $137.36, for a total transaction of $274,720.00. Following the completion of the sale, the insider directly owned 479 shares of the company’s stock, valued at $65,795.44. The trade was a 80.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,097 shares of company stock worth $4,860,156. 1.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

ICUI has been the subject of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. KeyCorp lowered their price objective on ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research report on Monday, April 21st. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Sunday, May 18th. Finally, Raymond James Financial reduced their target price on ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a research note on Friday, May 9th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, ICU Medical currently has a consensus rating of “Buy” and a consensus price target of $192.67.

ICU Medical Trading Down 1.8%

ICUI stock opened at $122.47 on Friday. The company has a current ratio of 2.59, a quick ratio of 1.52 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 12-month low of $117.92 and a 12-month high of $196.26. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of -31.98 and a beta of 0.87. The business’s 50-day moving average is $132.57 and its 200 day moving average is $143.90.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.49. The business had revenue of $599.49 million for the quarter, compared to analysts’ expectations of $574.15 million. ICU Medical had a positive return on equity of 6.75% and a negative net margin of 3.87%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.96 EPS. On average, sell-side analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.